Clopidogrel Vs. Aspirin in Patients with S. Aureus Bacteremia

Launched by TODD C. LEE MD MPH FIDSA · Oct 18, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating whether switching from aspirin to clopidogrel can improve health outcomes for patients who have a serious bacterial infection called S. aureus bacteremia. Patients in the study are already taking aspirin to help prevent heart problems. The researchers want to find out if clopidogrel, which may also help fight the S. aureus bacteria, could be a better option for these individuals.

To be eligible for this trial, patients need to be between the ages of 65 and 74 and currently taking aspirin for heart disease prevention. However, they cannot have active bleeding issues, need to avoid major surgeries in the near future, and should not be pregnant or allergic to clopidogrel. Participants will be randomly assigned to either continue taking aspirin or switch to clopidogrel. The study is still in the planning stages, so no one is being recruited yet. If the results are positive, it could lead to further studies to explore clopidogrel's benefits for more patients.

Gender

ALL

Eligibility criteria

• • The participant must meet all inclusion and exclusion criteria for the SNAP
• Platform (NCT05137119) and also the following inclusion and exclusion criteria:
• Inclusion Criteria:
• • Patient is taking aspirin for secondary prevention of cardiovascular disease (coronary, cerebrovascular, or peripheral vascular disease)
• Exclusion Criteria:
• • Active bleeding (allowing up to 3 days from platform entry to randomize in the event anti-thrombotic therapy is resumed)
• • Anticipated major cardiac surgery, neurosurgery, or spine surgery within the next 3 days
• • Pregnancy
• • Known receipt of clopidogrel, prasugrel, or ticagrelor within the last month
• • Allergy to clopidogrel
• • Concomitant receipt of oral Xa inhibitor